Successful treatment of a patient with lymphocyte-predominant Hodgkin's lymphoma with yttrium-90-ibritumomab tiuxetan

被引：2
|
作者：
Zojer, Niklas [1 ]
Mirzaei, Siroos [2 ]
Ludwig, Heinz [1 ]
机构：
[1] Wilhelminenspital Stadt Wien, Dept Med 1, Ctr Oncol & Hematol, Vienna, Austria
[2] Wilhelminenspital Stadt Wien, Dept Nucl Med, Vienna, Austria
来源：
EUROPEAN JOURNAL OF HAEMATOLOGY | 2008年 / 81卷 / 04期
关键词：
Hodgkin disease; antibodies; monoclonal; lymphoma; B-cell; antigens; CD20; radioimmunotherapy; ibritumomab tiuxetan; yttrium radioisotopes;
D O I：
10.1111/j.1600-0609.2008.01107.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Lymphocyte-predominant Hodgkin's lymphoma (LPHL) is known to be radiosensitive, and radiotherapy often forms part of the treatment of patients with stage III or IV LPHL. In addition, as LPHL is thought to arise from a germinal centre B-cell, and LPHL cells express the B-cell marker CD20 there is a rationale for using anti-CD20 therapies for the treatment of LPHL. We report a 42-yr-old man with stage III B LPLH who underwent successful treatment of LPHL with (90)Y-ibritumomab tiuxetan. To our knowledge, this is the first report on the use of an anti-CD20 radiolabeled antibody for the treatment of LPHL.
引用
收藏
页码：322 / 324
页数：3
相关论文
共 50 条
  • [1] Yttrium-90-ibritumomab tiuxetan radioimmunotherapy - A new treatment approach for B-cell non-Hodgkin's lymphoma
    Witzig, TE
    DRUGS OF TODAY, 2004, 40 (02): : 111 - 119
  • [2] Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
    McKinney, Matthew S.
    Beaven, Anne W.
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2014, 4 : 45 - 59
  • [3] 90Yttrium-ibritumomab tiuxetan:: a novel treatment for non-Hodgkin's lymphoma
    Blum, KA
    Bartlett, NL
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (08) : 1323 - 1331
  • [4] Yttrium 90 ibritumomab tiuxetan in lymphoma
    Cheung, Matthew C.
    Haynes, Adam E.
    Stevens, Adrienne
    Meyer, Ralph M.
    Imrie, Kevin
    LEUKEMIA & LYMPHOMA, 2006, 47 (06) : 967 - 977
  • [5] Treatment of lymphocyte-predominant Hodgkin lymphoma
    Engert, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 45 - 46
  • [6] Lymphocyte-predominant Hodgkin's lymphoma
    Kriz, J.
    Mueller, R.-P.
    Engert, A.
    Eich, H. T.
    ONKOLOGE, 2010, 16 (01): : 41 - +
  • [7] Lymphocyte-Predominant Hodgkin's Lymphoma
    Horwich, Alan
    Cunningham, David
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) : E325 - E325
  • [8] Lymphocyte-predominant Hodgkin's lymphoma: patient characteristics and outcomes
    Nature Clinical Practice Oncology, 2008, 5 (4): : 183 - 183
  • [9] Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's lymphoma
    Schnell, Roland
    Dietlein, Markus
    Schomaecker, Klaus
    Kobe, Carsten
    Borchmann, Peter
    Schicha, Harald
    Hallek, Michael
    Engert, Andreas
    ONKOLOGIE, 2008, 31 (1-2): : 49 - 51
  • [10] Lymphocyte-Predominant Hodgkin's Lymphoma Reply
    Canellos, George P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) : E326 - E326
12345